Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR ...

Myasthenia gravis (MG) is a chronic autoimmune condition that affects signaling between the body’s nerves and muscles, leading to muscle weakness. Symptoms of MG can appear anywhere on the body ...

Introduction: Thymoma-associated myasthenia gravis (TAMG) accounts for 15–20% of all myasthenia gravis (MG) cases and is typically characterized by severe clinical manifestations and suboptimal ...

Myasthenia gravis (MG) is a rare, chronic neuromuscular autoimmune disease with a median global prevalence of 10 per 100,000 and an in-hospital mortality rate of 1.8%. The hallmark of MG pathology is ...

Andrea Divis was shocked to learn that her symptoms of fatigue, blurred vision, and muscle weakness were due to a rare condition called myasthenia gravis. Here’s how she educated herself and ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile in adult patients with generalized myasthenia gravis, offering a promising ...

SAN DIEGO — Inebilizumab (Uplizna, Amgen) is safe and effective up to 52 weeks in patients with generalized myasthenia gravis (MG), new research suggested. If approved, the drug would ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...